3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
1
Non-Muscle Invasive Bladder Neoplasms
1
Carcinoma in Situ
1
Interventions
pembrolizumab
118
Carboplatin
101
Paclitaxel
62
Cisplatin
56
Gemcitabine
55
Pemetrexed
52
Bevacizumab
49
Docetaxel
44
Fluorouracil
39
Oxaliplatin
37
Dexamethasone
34
130-nm albumin-bound paclitaxel
33
atezolizumab
32
Leucovorin
32
Cetuximab
31
durvalumab
26
Nivolumab
25
Capecitabine
25
Rituximab
24
Prednisone
24
Fulvestrant
23
Cyclophosphamide
23
Lenalidomide
22
enzalutamide
21
venetoclax
20
Irinotecan
19
Letrozole
18
pomalidomide
16
apalutamide
16
daratumumab
15
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
BCG Vaccine
×
30 days
×
Clear all
NCT06833073
2026-05-28
INTerpath-011
Merck Sharp & Dohme LLC
Phase 2
Recruiting
308 enrolled